<DOC>
	<DOCNO>NCT00010413</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine response rate 1-year event-free survival patient refractory pemphigus treat high-dose cyclophosphamide .</brief_summary>
	<brief_title>Phase II Study High-Dose Cyclophosphamide Patients With Refractory Pemphigus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive cyclophosphamide IV day 1-4 filgrastim ( G-CSF ) begin day 10 continue blood count recover . Patients follow monthly 6 month , every 2 month 6 month , every 4 month year , annually thereafter .</detailed_description>
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Definitive diagnosis pemphigus , include follow : Typical clinical lesion Histologically proven skin mucous membrane biopsy Pemphigus IgG autoantibodies skin mucous membrane direct immunofluorescence ( IF ) Circulating pemphigus IgG autoantibodies serum indirect IF Dependence highdose corticosteroid Persistent disease activity despite treatment mycophenolate mofetil azathioprine , inability tolerate drug ( paraneoplastic pemphigus , persistent disease activity despite treatment cyclosporine ) Prior/Concurrent Therapy No concurrent cytotoxic therapy Patient Characteristics Performance status : Karnofsky 20100 % Renal : Creatinine great 2.5 mg/dL Cardiovascular : LVEF least 40 % Pulmonary : FVC , FEV1 , DLCO least 50 % predict Other : Not pregnant Fertile patient must use effective contraception 9 month study Not preterminal moribund</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>pemphigus</keyword>
	<keyword>rare disease</keyword>
</DOC>